CagriSema produced 14.2% average weight loss at 68 weeks, compared with 10.2% for semaglutide 2.4 mg, in the 2026 REIMAGINE 2 Phase 3 trial’s efficacy analysis. The study enrolled adults with type 2 diabetes.
Sometimes “two signals are better than one” is just a sales line. REIMAGINE 2 is useful because it actually tested that idea: the combination was compared directly with semaglutide and cagrilintide on their own.
What REIMAGINE 2 showed
The cagrilintide-plus-semaglutide combination beat either component alone on average weight loss in the same Phase 3 trial.
CagriSema
14.2% average weight loss.
Semaglutide
10.2% at the matching 2.4 mg level.
Study group
Adults with type 2 diabetes over 68 weeks.
What is CagriSema?
CagriSema combines cagrilintide and semaglutide in one once-weekly research program.
- Cagrilintide is a long-acting version of amylin, a meal-related fullness signal.
- Semaglutide is a GLP-1 receptor agonist, which acts on a different appetite and blood-sugar pathway.
The commercial idea is simple: use two different signals instead of asking one signal to do all the work.
For a plain-English explanation of the first component, read what is cagrilintide?. Our cagrilintide vs semaglutide guide explains why amylin and GLP-1 are not the same pathway.
What did REIMAGINE 2 test?
REIMAGINE 2 was a 68-week Phase 3 trial with 2,713 adults who had type 2 diabetes that was not adequately controlled with metformin, with or without an SGLT2 inhibitor.
The trial compared the combination against both of its parts and placebo. That direct design is a major strength because every group followed the same general study calendar and entry rules.
Under the efficacy analysis, which estimates the effect if people followed the planned treatment, the 2.4 mg comparison looked like this:
| Weekly study group | Average weight change at week 68 | Average HbA1c change |
|---|---|---|
| CagriSema 2.4/2.4 mg | -14.2% | -1.91 points |
| Semaglutide 2.4 mg | -10.2% | -1.75 points |
| Cagrilintide 2.4 mg | -8.4% | -0.80 points |
| Placebo | -1.5% | +0.09 points |
HbA1c is a blood test that reflects average blood sugar over the previous few months. Lower is generally the goal in this type of diabetes study.
Did the combination really outperform semaglutide?
Yes, within this trial and under the reported efficacy analysis. Average weight loss was 14.2% with CagriSema 2.4/2.4 mg and 10.2% with semaglutide 2.4 mg, a difference of four percentage points.
The study also tested a lower 1/1 mg combination. That group averaged 12.0% weight loss, compared with 7.5% for semaglutide 1 mg.
This makes REIMAGINE 2 more informative than comparing two unrelated headlines. The same study directly compared:
- combination versus semaglutide;
- combination versus cagrilintide; and
- two different combination levels.
It does not prove that every person will lose 14.2%, and it does not compare CagriSema directly with tirzepatide or retatrutide.
Why are some reports using 12.9% instead of 14.2%?
The trial used two common statistical views.
- The efficacy analysis asked what the result would look like if participants followed the planned treatment. It reported 14.2% for CagriSema 2.4/2.4 mg.
- The treatment-regimen analysis included the effect of events such as stopping treatment. It reported 12.9% for the same combination level.
Both are real study numbers. They answer slightly different questions. A useful article labels the analysis instead of choosing the bigger number without context.
What side effects were reported?
Digestive events were the most common. In the 2.4 mg comparison, gastrointestinal events were reported by 67.2% of the CagriSema group and 53.9% of the semaglutide group.
Stopping because of adverse events occurred in 8.5% of the CagriSema 2.4/2.4 mg group and 6.6% of the semaglutide 2.4 mg group.
That tradeoff belongs next to the headline result: the combination produced a larger average weight change, while digestive events were also more common. Phase 3 gives a much better estimate than a small early trial, but ongoing study and regulatory review still matter.
How is REIMAGINE 2 different from REDEFINE 1?
Both are large CagriSema trials, but they answer different search questions.
| REIMAGINE 2 | REDEFINE 1 | |
|---|---|---|
| Main population | Adults with type 2 diabetes | Adults with obesity or overweight, without diabetes |
| Duration | 68 weeks | 68 weeks |
| Headline CagriSema efficacy result | 14.2% average weight loss | 22.7% average weight loss |
| Best use of the result | Diabetes-specific combination comparison | Obesity-specific combination comparison |
People with type 2 diabetes often lose less weight on average in obesity-drug trials than people without diabetes. That is why the two percentages should not be treated as a contradiction.
Why this result matters commercially
The Phase 3 result strengthens a clear market idea: future metabolic products may be sold around combinations of complementary pathways, not only stronger versions of one GLP-1 signal.
For research buyers, that makes the purchase order more specific—not less. The word “CagriSema” is not enough for a laboratory specification. A combination request should state:
- the exact identity of cagrilintide;
- the exact identity of semaglutide;
- the amount and ratio of each component;
- whether each component was tested before blending;
- which final-blend checks were performed; and
- which batch numbers connect the labels and COAs.
Certiva’s cagrilintide research page provides current product specifications, and buyers can request the active batch COA before an order. The batch traceability guide shows how the label, report and supplied material should connect.
The bottom line
The REIMAGINE 2 answer is direct: CagriSema 2.4/2.4 mg averaged 14.2% weight loss at 68 weeks versus 10.2% with semaglutide 2.4 mg in adults with type 2 diabetes under the efficacy analysis.
The combination also produced more digestive events. It remains investigational, but the direct Phase 3 comparison gives the amylin-plus-GLP-1 idea meaningful support instead of marketing language alone.
Review current cagrilintide research specifications →
Sources and further reading
- Novo Nordisk: REIMAGINE 2 Phase 3 results
- ClinicalTrials.gov: REIMAGINE 2 NCT06065540
- The Lancet Diabetes & Endocrinology: REIMAGINE 2 study
This article explains public research reported through August 8, 2026. CagriSema remains investigational and is not offered here as a medicine or for personal use.
Frequently asked questions
What did CagriSema achieve in REIMAGINE 2?
In the 2026 REIMAGINE 2 Phase 3 trial, CagriSema 2.4/2.4 mg produced 14.2% average weight loss at 68 weeks versus 10.2% with semaglutide 2.4 mg under the efficacy analysis.
What is CagriSema?
CagriSema is an investigational once-weekly combination of cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 receptor agonist.
Did CagriSema lower HbA1c more than semaglutide?
Yes. In REIMAGINE 2, the 2.4/2.4 mg combination reduced HbA1c by 1.91 percentage points versus 1.75 points with semaglutide 2.4 mg under the efficacy analysis.
Was REIMAGINE 2 a direct comparison?
Yes. The Phase 3 trial directly compared CagriSema with matching doses of semaglutide, cagrilintide and placebo in adults with type 2 diabetes.
Is CagriSema approved?
No. CagriSema remains investigational. The REIMAGINE 2 findings are Phase 3 evidence but do not make the combination an approved medicine.
What should a buyer verify when sourcing a peptide combination?
Verify the exact identity and amount of each component, the blend ratio, batch-specific testing, packaging, storage requirements and whether the COA matches the supplied batch.
For research use only. Not for human consumption. This article is educational and makes no medical, therapeutic, or dosing claims.
← More gLP-1 & weight management guides · Have a question? Start an inquiry →